Is Lupin (LUPIN) overvalued or fairly valued?

MarketChacha shows Lupin's valuation in context — a forward P/E of about 24.2, a price-to-book of about 5.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Lupin's revenue?

Lupin reported revenue of ₹27,958 Cr for FY2026, with net profit of ₹5,333 Cr, per official filings.

What is the share price of Lupin (LUPIN)?

Lupin last traded at ₹2,495.30 (+2.1% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Lupin

LUPIN · NSE · Pharma · India

₹2,495.30+2.1%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:37 AM

Snapshot

TickerLUPIN

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees26,021

HeadquartersMumbai, India

Market cap₹1,13,326 Cr

P/B5.0

Volume1.96L

Websitewww.lupin.com

Filings tracked0

About Lupin

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters47.0%
Institutions34.8%
Public & other18.2%

230 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend2.6% → 19.1%

Margin has expanded by about 16.5 points — the business is getting more profitable.

Growth qualityrev 19% · PAT 131%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹7,913 Cr · EPS 26.80

Est. earnings growth -17.0%

Next fiscal year

Rev ₹31,246 Cr · EPS 102.30

Est. earnings growth +1.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹1,836.8052-wk range₹2,529.50

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹1,13,326 Cr

Day change

+2.1%

Fwd P/E

24.2

P/B

5.0

Div yield

0.74%

Beta

0.18

Revenue (FY2026)

₹27,958 Cr

Net margin

19.1%

Revenue CAGR (3y)

+18.9%

Profit CAGR (3y)

+131.5%

Net profit (FY2026)

₹5,333 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about LUPIN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹27,958 Cr	₹5,333 Cr	19.1%
FY2025	₹22,708 Cr	₹3,282 Cr	14.5%
FY2024	₹20,011 Cr	₹1,914 Cr	9.6%
FY2023	₹16,642 Cr	₹430 Cr	2.6%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹7,475 Cr	₹1,460 Cr	19.5%
2025Q4	₹7,168 Cr	₹1,176 Cr	16.4%
2025Q3	₹7,048 Cr	₹1,478 Cr	21.0%
2025Q2	₹6,258 Cr	₹1,219 Cr	19.5%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.